KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Sales and Divestitures (2016 - 2020)

Esperion Therapeutics filings provide 4 years of Gains from Sales and Divestitures readings, the most recent being $53587.0 for Q2 2020.

  • On a quarterly basis, Gains from Sales and Divestitures rose 427.95% to $53587.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $53587.0, a 427.95% increase, with the full-year FY2019 number at $17710.0, up 415.27% from a year prior.
  • Gains from Sales and Divestitures hit $53587.0 in Q2 2020 for Esperion Therapeutics, up from $10089.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $53587.0 in Q2 2020 to a low of $1562.0 in Q1 2018.
  • Median Gains from Sales and Divestitures over the past 4 years was $6248.0 (2017), compared with a mean of $11341.5.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 44.99% in 2018 and later soared 427.95% in 2020.
  • Esperion Therapeutics' Gains from Sales and Divestitures stood at $6248.0 in 2017, then tumbled by 44.99% to $3437.0 in 2018, then skyrocketed by 415.27% to $17710.0 in 2019, then skyrocketed by 202.58% to $53587.0 in 2020.
  • The last three reported values for Gains from Sales and Divestitures were $53587.0 (Q2 2020), $10089.0 (Q1 2020), and $17710.0 (Q4 2019) per Business Quant data.